Clinical specialties, therapeutic interventions, and pharmacomicrobiomics
| Specialty | Drug Class | Example | Reference |
|---|---|---|---|
| Oncology | Immune checkpoint inhibitor | Anti-programmed cell death 1 protein | Gopalakrishnan et al., 2018; Routy et al., 2018 |
| Anti–CTLA-4 antibodies | Alexander et al., 2017 | ||
| Antineoplastic enzyme inhibitor | Irinotecan | Wallace et al., 2010 | |
| Anthracycline | Doxorubicin | Yan et al., 2017 | |
| Alkylating agent | Cyclophosphamide | Alexander et al., 2017 | |
| Cardiology | Statin | Lovastatin | Yoo et al., 2014 |
| Cardiac glycoside | Digoxin | Haiser et al., 2013 | |
| Diabetes | Biguanide | Metformin | Wu et al., 2017 |
| Gastroenterology | Sulfa drug | Sulfasalazine | Peppercorn and Goldman, 1972b |
| Psychiatry | Antipsychotic | Olanzapine | Davey et al., 2012 |
| Risperidone | Bahr et al., 2015 | ||
| Benzodiazepine | Bromazepam | Fujii et al., 1987 | |
| Clonazepam | Elmer and Remmel, 1984 | ||
| Nitrazepam | Takeno and Sakai, 1991 | ||
| Neurology | Precursor | L-Dopa | Bergmark et al., 1972 |